

April 14, 2023

To Whom it may concern

Sumitomo Mitsui Trust Bank, Limited

Notice regarding Investment in Healthcare New Platform Fund

Managed by Whiz Partners Inc.

Sumitomo Mitsui Trust Bank, Ltd (President: Kazuya Oyama, hereinafter referred to as "SuMi TRUST Bank") is pleased to announce that as a strategic partner we have decided to make investments in Healthcare New Platform Fund Investment Limited partnership (Hereinafter "HNP Fund") as a Limited Partnership (Hereinafter "LP").

1. Background

The lack of access to appropriate medical care due to various factors such as education, income disparity, and unmet medical needs (diseases for which effective treatment methods have not been established) has become a social issue, and it is partly due to the fact that the cost of drug development is rising year by year.

In order to reduce drug development costs, the pharmaceutical industry is required to shift from a vertically integrated model of drug development processes to a horizontal division of labor model that utilizes outsourcing.

2. Outline of the Project

(1) Fund Overview

Fund Name	Healthcare New Platform Fund Investment Limited partnership
Investment Management Company	Whiz Partners Inc.
Investment Targets	Healthcare Platform Company

(2) Outline of the asset management company

Whiz Partners Inc., the manager of the HNP Fund, is an independent investment management company based in Tokyo that focuses on alternative assets such as growth investments and global macro investments. In addition to the healthcare field, we are also familiar with technology fields such as information technology and artificial intelligence. We are also a signatory to Japan Impact-driven Financing Initiative (*1), which conducts impact investing that pursues the simultaneous creation of positive and measurable social and environmental impacts in parallel with financial returns through the development of investee companies.

The HNP Fund will invest to new platform companies in healthcare, including Axcelead, Inc. (*2), the first healthcare platform company in Japan that started business by taking over Takeda Pharmaceutical Company's drug discovery platform business, and ARCALIS, Inc., which provides drug discovery support, as well as contract development and manufacturing business (CDMO business) for messenger RNA therapeutics and vaccines.

3. Our Role

In order to financially support challenges and initiatives aimed at solving social issues, we are promoting 500 billion yen in impact equity investment initiatives toward 2030. We have been working to create new investment opportunities and collaborate with our customers in these fields, including LP investments in the life science field. With this investment, we will further strengthen these activities and support the growth of Japan global healthcare platform companies to further contribute to solving the social issue of "unmet medical needs" and developing the drug discovery ecosystem in Japan.

*1 Japan Impact-driven Financing Initiative

An initiative in which multiple financial institutions that believe that the purpose of financial institutions is to comprehensively grasp impacts and lead to the resolution of environmental and social issues, and promote the practice of impact-oriented investment and lending (<https://www.impact-driven-finance-initiative.com/en/>)

*2 Axcelead, Inc. (https://www.axcelead-hd.com/?page_id=825)

Axcelead is a group of companies that develops a drug discovery platform business centered on Axcelead Drug Discovery Partners, Inc. (ADDP), Japan's first integrated drug discovery solution provider, which took over Takeda's drug discovery platform business in 2017. In Axcelead, not only ADDP, but there are three more subsidiaries, including ARCALIS, Inc. (<https://corp.arcalis.co.jp/>), A-Digital, Inc., established in response to a partial business

transfer from Hitachi High-Tech Co., Ltd., to develop a drug discovery digital platform that improves drug discovery efficiency 100 times by promoting the digitalization of all processes of drug discovery, and PassPort Technologies, Inc., a San Diego-based company that develops formulation of drugs combination with next-generation transdermal drug delivery technology.

Ends